Head-to-head · WeighScore
GoodRx vs Trillium Meds
The verdict
GoodRx takes it — 69.6/100 to 69.4/100, but only just.
GoodRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform. Trillium Meds is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | GoodRx | Trillium Meds |
|---|---|---|
| WeighScore | 69.6/100 | 69.4/100 |
| Grade | C | C |
| Scorecard rank | #116 | #124 |
| Semaglutide | Not disclosed | $119/mo (3-month plan, compounded) |
| Tirzepatide | $299/mo (brand Zepbound) | $199/mo (3-month plan, compounded) |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #116 · C
Strengths
- $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
- $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
- Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
- No membership fee — bring your own prescription and present the discount card at the pharmacy counter
- Brand-name FDA-approved medication, not compounded
Where it loses points
- Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
- Self-pay only — does not apply toward insurance benefits or deductibles
- Headline price applies to the lowest Foundayo dose; higher doses may cost more
- No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
- Pricing can change as Lilly's manufacturer coupon program evolves
Graded #124 · C
Strengths
- LegitScript certified with an active seal; serves all 50 states plus Puerto Rico with no geographic restrictions
- All-inclusive pricing covers medication, provider consultation, and shipping with no hidden fees or add-ons
- Two pharmacy options (BPI Labs with B6, ProRx) and three plan structures: 1-month, 3-month fixed, or 3-month titrated
- Small owner-operated; founder personally handles customer support outside business hours for direct, responsive service
- Klarna and Affirm financing available; pause anytime with no long-term commitment required
Where it loses points
- No labs, coaching, or clinical monitoring included — telehealth Rx and pharmacy fulfillment only
- Small single-operator platform may limit capacity and support consistency as patient volume grows
- Compounded medications are not FDA-approved; newer platform with limited long-term public track record
- Tirzepatide from $199/mo (3-mo plan) is mid-market; sema from $119/mo competitive but not lowest available
- No live video consult disclosed; async intake-form-based provider review by external licensed provider network
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.